comparemela.com

Latest Breaking News On - Outlayer item - Page 1 : comparemela.com

FDA grants priority review to mosunetuzumab for relapsed or refractory follicular lymphoma

The FDA granted priority review to mosunetuzumab for treatment of certain patients with relapsed or refractory follicular lymphoma.The designation applies to use of the agent by adults who received at least two prior systemic therapies.

Study explores perspectives of Indigenous patients with CKD

Researchers identified five common themes among Indigenous patients with chronic kidney disease when exploring their relationship with health care, according to data published in Kidney International.“Indigenous peoples are defined as those who first lived in a region and have distinct cultural traditions, knowledge and language which provides a basis for positive self-image and healthy

Massive uncertainty : Health care providers seek answers in wake of Roe v Wade decision

With the U.S. Supreme Court’s decision to overturn Roe v. Wade, health care providers are questioning how to help patients legally navigate reproductive care. After the ruling, several states moved to immediately ban abortions through so-called “trigger laws.” Jessie Hill, JD, the associate dean for research and faculty development and a professor at the Case Western University

DaVita CEO: In ruling, US Supreme Court took narrow view of dialysis payment provision

U.S. Supreme Court justices made a “narrow” interpretation of Medicare’s Secondary Payer provision when ruling against DaVita Inc. in a case about how group health plans pay for dialysis care, the company CEO told investors.“ . We believe that the ruling ignores the long history of protection offered under the Medicare Secondary Payer Act [MSPA] to the dialysis patient

Top in hem/onc: Cancer survivorship; impact of COVID-19 on breast cancer care

According to a new report from the American Cancer Society, in collaboration with the National Cancer Institute, the number of cancer survivors in the United States has risen to 18 million.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.